TG Therapeutics (OTCMKTS:TGTX – Get Free Report) released its quarterly earnings results on Monday. The company reported $2.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $2.22, reports.
TG Therapeutics Price Performance
TG Therapeutics Company Profile
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma.
Featured Articles
- Five stocks we like better than TG Therapeutics
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- 3 Safe and Steady Stocks for Any Market
- What is a Special Dividend?
- Is Lemonade Stock Set for a Big Squeeze After Earnings?
- Stock Analyst Ratings and Canadian Analyst Ratings
- Caterpillar Stock Could Top $650 by Year’s End
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
